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Shiga-toxigenic Escherichia coli (STEC) are re-
sponsible for food poisoning outbreaks and can 
cause serious human gastrointestinal disease, 
sometimes leading to life-threatening compli-
cations  such  as  hemolytic  uremic  syndrome 
(HUS; Nataro and Kaper, 1998; Paton and 
Paton, 1998; Bettelheim, 2007). Other than Shiga 
toxin, some STEC strains also produce subti-
lase cytotoxin (SubAB). SubAB is an AB5 toxin 
consisting of a catalytic A subunit and five B 
subunits that form a pentameric ring responsi-
ble for binding to the receptor on the host cell 
surface. In mice, SubAB causes systemic organ 
failure that may ultimately result in death (Paton 
et al., 2004; Wang et al., 2007).
The A subunit of SubAB is a serine protease 
that specifically cleaves and inactivates immuno-
globulin heavy chain–binding protein (BiP)/glu-
cose-regulated protein 78, a heat shock protein 
70 family member (Paton et al., 2006). Mutation 
of the Ser272 residue to alanine in the Asp-His-
Ser catalytic triad of the A subunit inactivates 
SubAB (Paton et al., 2004). This mutant version 
of SubAB has been used for vaccination and elic-
its antibodies that protect against a challenge with 
native  SubAB  or  SubAB-producing  bacteria 
(Talbot et al., 2005). Cytotoxicity of SubAB has 
been convincingly demonstrated to result from 
the cleavage of BiP at a dileucine motif (Leu417, 
Leu418 in mouse BiP) because overexpression of 
BiP in which the SubAB cleavage site has been 
eliminated protects cells from SubAB-induced 
cytotoxicity (Paton et al., 2006).
BiP fulfills several essential functions in the 
ER. As a chaperone, BiP assists in the folding 
and assembly of nascent secretory proteins by 
binding to them transiently, and BiP remains 
associated with mutant misfolded proteins (Bole 
et al., 1986; Gething et al., 1986; Pelham, 1986). 
In addition, BiP may play a role in gating the 
Sec61 complex or translocon (Hamman et al., 
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Shiga-toxigenic Escherichia coli (STEC) use subtilase cytotoxin (SubAB) to interfere with 
adaptive immunity. Its inhibition of immunoglobulin secretion is both rapid and profound. 
SubAB favors cleavage of the newly synthesized immunoglobulin heavy chain–binding 
protein (BiP) to yield a C-terminal fragment that contains BiP’s substrate-binding domain. 
In the absence of its regulatory nucleotide-binding domain, the SubAB-cleaved C-terminal 
BiP fragment remains tightly bound to newly synthesized immunoglobulin light chains, 
resulting in retention of light chains in the endoplasmic reticulum (ER). Immunoglobulins 
are thus detained in the ER, making impossible the secretion of antibodies by SubAB-
treated B cells. The inhibitory effect of SubAB is highly specific for antibody secretion, 
because other secretory proteins such as IL-6 are released normally from SubAB-treated  
B cells. Although SubAB also causes BiP cleavage in HepG2 hepatoma cells, (glyco)protein 
secretion continues unabated in SubAB-exposed HepG2 cells. This specific block in antibody 
secretion is a novel means of immune evasion for STEC. The differential cleavage of newly 
synthesized versus “aged” BiP by SubAB in the ER provides insight into the architecture of 
the ER compartments involved.
©  2009  Hu  et  al.  This  article  is  distributed  under  the  terms  of  an  Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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as a control. We found that BiP was cleaved into two fragments, 
representing the N-terminal NBD (44 kD) and the C-ter-
minal SBD (28 kD) in SubAB-exposed B cells (Fig. 1 A). 
In contrast, protein disulfide isomerase (PDI), AAA ATPase 
(p97), calnexin, calreticulin, and ERdj3 were affected neither 
quantitatively nor qualitatively by exposure of B cells to 
SubAB. SubAB-mediated depletion of BiP induces an UPR 
in many cell types (Takano et al., 2007; Hayakawa et al., 2008; 
1998),  in  translocation of nascent proteins across the ER 
membrane (Matlack et al., 1999), in dislocation of misfolded 
proteins from the ER for degradation (Chillarón and Haas, 
2000), and in activation of the unfolded protein response 
(UPR; Bertolotti et al., 2000; Shen et al., 2002). BiP contains 
a nucleotide-binding domain (NBD) at its N terminus and a 
substrate-binding domain (SBD) at its C terminus. A KDEL 
sequence at its C-terminal end ensures BiP’s retention in the 
ER (Haas and Meo, 1988). SubAB inactivates BiP through 
proteolytic  cleavage,  which  separates  the  N-terminal  NBD 
from the C-terminal SBD (Paton et al., 2006). SubAB-mediated 
BiP inactivation has been linked to decreased virion assembly 
of human cytomegalovirus (Buchkovich et al., 2008), re-
duced  ER-associated  degradation  of  proteins  (Lass  et  al., 
2008), and induction of the UPR in various cell types (Takano 
et al., 2007; Hayakawa et al., 2008; Morinaga et al., 2008; 
Wolfson et al., 2008).
A primary target for SubAB may be the spleen. Mice in-
jected with SubAB exhibit splenic atrophy and lose 60% of 
spleen weight 3 d after injection (Paton et al., 2004; Wang 
et al., 2007). B cells represent the major lymphocyte population 
in the spleen responsible for secretion of antibodies, both so-
called natural antibodies and those elicited by immunization. 
The B cell responds to encounter of its cognate antigen by 
ramping up the synthesis and secretion of immunoglobulins. 
BiP is a key player in assisting the folding and assembly of 
immunoglobulin heavy and light chains (Bole et al., 1986; 
Knittler and Haas, 1992). Thus, intoxication with SubAB 
and subsequent BiP cleavage could have a profound impact 
on the function of B cells, specifically with regard to immuno-
globulin assembly and secretion. In addition, no BiP knock-
out  model  is  available  that  demonstrates  whether  BiP’s 
function is indeed indispensable in B cells or whether BiP can 
be replaced, entirely or in part, by other chaperones. BiP is 
believed to also assist in the folding and assembly of other 
membrane or secreted proteins (Fourie et al., 1994; Gething 
and Sambrook, 1992; Gething, 1999; Ma and Hendershot, 
2001), but there is no easy way to distinguish the client pro-
teins that require BiP from those that do not.
Here, we describe the effect of SubAB on B cell function 
and show that it blocks secretion of immunoglobulins, but 
not of other proteins we examined. We propose a model that 
describes how SubAB targets newly synthesized BiP and gen-
erates a cleaved BiP fragment that preferentially sequesters 
the newly synthesized light chains. This causes a blockade in 
antibody secretion by activated B cells. Our results illustrate 
how pathogenic STEC subvert the host’s immune system 
and do so rapidly.
RESULTS
BiP is the ER substrate for SubAB in B cells
To confirm that BiP is the substrate for SubAB (Paton et al., 
2006) in mouse B cells, we treated B cells with SubAB and 
examined the toxin’s effect on a select group of ER proteins, 
in addition to BiP itself. In all experiments, we used the cata-
lytically inactive, mutant version of SubAB (Paton et al., 2006) 
Figure 1.  SubAB cleaves BiP and induces the UPR in B cells. (A) BiP 
is a specific target for SubAB in B cells. B cells purified from spleens of 
MD4 mice were cultured in LPS (20 µg/ml) to induce differentiation.  
3-day LPS-stimulated B cells were treated with 0.1 µg/ml mutant or native 
SubAB for 3 h before lysis. Lysates were immunoblotted using antibodies 
against the BiP N terminus or C terminus; PDI; AAA-ATPase (p97); cal-
nexin; calreticulin; ERdj3 (an HSP40 family protein); and actin. (B) IRE-1/
XBP-1 and PERK pathways are activated in B cells in response to SubAB 
treatment. Similar lysates were immunoblotted using antibodies against 
BiP at its N terminus, IRE-1, XBP-1, phospho-eIF2, eIF2, p97, and actin. 
(C) 1-d LPS-stimulated B cells were treated with 0.1 µg/ml mutant or 
native SubAB or dithiothreitol (DTT) for 3 h before lysis. Lysates were  
immunoblotted using antibodies against IRE-1, XBP-1, p97, and actin. 
Results shown in each panel are representative of three independent 
experiments. For each experiment, B cells were pooled from at least two 
mouse spleens.JEM VOL. 206, October 26, 2009 
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BiP occurs within 15 min after addition of SubAB and reaches 
a plateau after a 30-min exposure (Fig. 2 A). The resultant 
C-terminal BiP fragment is stable throughout the course of 
the experiment, but the N-terminal BiP fragment is less so. 
The fate of the cleaved BiP fragments may include their re-
moval from the ER, followed by degradation. We further 
explored the kinetics of BiP cleavage by pulse-chase analysis. 
We radiolabeled B cells for 4 h and chased them for 0, 15, 30, 
60, 120, or 180 min in the presence of native or mutant 
SubAB. In B cells treated with mutant SubAB, BiP degrades 
slowly, with 80% BiP remaining after the 180 min chase 
(Fig. 2 B), yielding a half-life in excess of 6 h, presumably re-
flecting the normal turnover rate of BiP. When treated with 
SubAB, 60% BiP was already cleaved within 30 min. BiP 
cleavage beyond this time point is less dramatic (Fig. 2 B). 
We  therefore  wondered  whether  SubAB  preferentially 
cleaves newly synthesized BiP, which is accessible to SubAB 
in the ER and presumably located at those sites where 
Morinaga et al., 2008; Wolfson et al., 2008). In SubAB-
exposed B cells, we observed a subtle yet clear increase in the 
apparent  molecular  weight  of  IRE-1,  which  is  consistent 
with IRE-1 phosphorylation (Fig. 1, B and C). Upon SubAB 
treatment, the level of XBP-1–spliced protein is up-regulated 
in 1-d LPS-stimulated B cells, but only moderately so in 
3-day LPS-stimulated B cells (Fig. 1, B vs. C), consistent with 
the fact that LPS itself is a potent UPR inducer for B cells 
(Reimold et al., 2001; Calfon et al., 2002). Activation of the 
PERK axis of the UPR was also examined. We found that 
phosphorylation of eIF2 increases slightly in response to 
SubAB treatment in 3-day LPS-stimulated B cells (Fig. 1 B).
SubAB preferentially cleaves newly synthesized BiP
To address the kinetics of BiP cleavage by SubAB, we incu-
bated 3-day LPS-stimulated B cells with SubAB for 0, 15, 30, 
60, 120, and 180 min, and assessed BiP cleavage by immuno-
blotting of total cell extracts. We observed that cleavage of 
Figure 2.  SubAB preferentially cleaves newly synthesized BiP in B cells. (A) BiP cleavage by SubAB reaches its maximum within 30 min. B cells 
purified from spleens of S/ mice were cultured in LPS (20 µg/ml) to induce differentiation. 3-day LPS-stimulated B cells were treated with 0.1 µg/ml 
mutant or native SubAB for the times indicated before lysis. Lysates were immunoblotted for full-length BiP, N-terminal BiP, C-terminal BiP, p97, and 
actin. (B) 3-day LPS-stimulated S/ B cells were labeled with [35S]methionine and [35S]cysteine for 4 h, chased for the indicated times in the presence 
of mutant or native SubAB, and lysed. Full-length BiP was immunoprecipitated from the lysates using an anti-KDEL antibody. Radioactive polypeptides 
were quantified using a phosphorimager. (C) Newly synthesized BiP is cleaved completely by SubAB. 3-day LPS-stimulated S/ B cells were radiolabeled 
for 10, 30, 60, or 240 min, chased for the indicated times in the presence of SubAB, and lysed. Full-length BiP was immunoprecipitated from the lysates 
using the anti-KDEL antibody. Radioactive polypeptides were quantified using a phosphorimager. (D) Aged BiP is not cleaved efficiently by SubAB. 3-day 
LPS-stimulated B cells were pretreated with CHX (100 µM) for 0, 1, 2, or 3 h and subsequently exposed to 0.1 µg/ml mutant or native SubAB for 2 h be-
fore lysis. Lysates were immunoblotted for full-length BiP, N-terminal BiP, p97, and actin. Intensities of protein bands in the full-length BiP immunoblot 
were determined using ImageJ (National Institutes of Health) and data were plotted. Results shown in each panel are representative of three independent 
experiments. For each experiment, B cells were pooled from at least two mouse spleens.2432 SUBTILASE CYTOTOXIN BLOCKS ANTIBODY SECRETION | Hu et al.
proteins enter the ER. We therefore radiolabeled B cells for 
10, 30, 60, and 240 min and chased these cells for 0, 30, 60, 
and 120 min in the presence of SubAB to examine whether 
newly synthesized BiP (10-min pulse) is indeed more sensi-
tive to SubAB-mediated cleavage. All samples were normal-
ized to equivalent amounts of radioactivity incorporated. 
Whereas newly synthesized BiP (10-min pulse) is cleaved by 
SubAB nearly completely within 2 h, BiP produced after 240 
min of labeling is far more resistant to cleavage (Fig. 2 C). 
We pretreated B cells with cycloheximide to block protein 
synthesis, allowed the pool of BiP to age in the absence of 
ongoing  protein  synthesis,  and  then  exposed  the  cells  to 
SubAB. Cycloheximide-treated cells contain more BiP resis-
tant to SubAB cleavage, consistent with the notion that newly 
synthesized BiP is the preferred target for SubAB (Fig. 2 D). 
All of these approaches yield a consistent result and lead us to 
the following conclusion: BiP found at sites in the ER where 
newly synthesized proteins are inserted is more readily cleaved 
than BiP that is given an opportunity to mature and move to 
more distal aspects of the ER. Although the entry pathway of 
SubAB remains to be explored in detail, our data suggest that 
delivery of SubAB targets those parts of the ER most directly 
involved in immunoglobulin folding/assembly/secretion.
SubAB blocks secretion of IgM and free  light chains
To examine the effect of SubAB treatment on B cell func-
tion, we stimulated naive B cells with LPS for 3 d, and radio-
labeled these cells in the presence of SubAB or the inactive 
mutant SubAB for 0, 20, 40, or 60 min. Total protein syn-
thesis within the 20-min labeling period is not affected by 
SubAB. Compared with control cells treated with mutant 
SubAB, exposure to SubAB for 40 and 60 min reduces pro-
tein synthesis by no more than 20 and 40%, respectively 
(Fig. S1; Morinaga et al., 2008).
To examine the effect of SubAB on secretion, we ex-
posed 3-day LPS-stimulated B cells to SubAB or to the inac-
tive mutant SubAB for 30 min, a time frame within which 
cleavage of BiP by SubAB should have reached its maximum 
and protein synthesis is not significantly affected (Fig. 2,   
A and B, and Fig. S1). We radiolabeled these SubAB-exposed 
cells for 10 min, chased them for 2 h (Fig. S2 A), and then 
examined immunoglobulin secretion by immunoprecipita-
tion. Secretion of IgM ceases after as little as 30 min of SubAB 
treatment (Fig. 3 A), coincident with intracellular retention 
of IgM (Fig. 3 B). Immunoprecipitates from the culture me-
dia using the anti- antibody contain not only assembled (to 
 chain) but also free  chains, explaining why a stronger 
 signal was observed compared with immunoprecipitations 
performed with the anti- antibody (Fig. 3 A). The data sug-
gest that free  chains were likewise retained in SubAB-
treated B cells. In S/ B cells, which make only membrane 
IgM and cannot secrete IgM, the secretion of free  chains is 
indeed blocked by SubAB treatment (Fig. 3 C). HepG2 cells, 
a human hepatocellular carcinoma cell line that secretes a 
variety of serum proteins, including 1-antitrypsin and albu-
min, were examined to see whether blocking of secretion is 
Figure 3.  SubAB blocks secretion of IgM and free  light chains. 
(A) 3-day LPS-stimulated MD4 B cells were pretreated with mutant or 
native SubAB for 30 min, labeled with [35S]methionine and [35S]cysteine 
for 10 min, and chased for the indicated times. Secreted IgM was immuno-
precipitated from the culture media using an anti- or - antibody.  
(B) 3-day LPS-stimulated MD4 B cells, treated and pulse-chased as de-
scribed in A, were lysed. IgM was immunoprecipitated from the lysates 
using anti- antibody. A longer exposed autoradiogram is shown for 
SubAB-treated samples. (C) 3-day LPS-stimulated S/ B cells were 
pretreated with mutant or native SubAB for 30 min, radiolabeled for  
10 min, and chased. The secreted free  chains were immunoprecipitated 
from the culture media using anti- antibody. Approximately seven times 
as much starting material was used for immunoprecipitations for the 
SubAB-treated samples to emphasize the differences in levels of secre-
tion. (D) HepG2 cells were treated with mutant or native SubAB during 
the 30-min radiolabeling period, and chased. Lysates were used for  
immunoprecipitation with an anti-KDEL antibody. (E) Culture media from 
toxin-treated, radiolabeled HepG2 cells were immunoprecipitated for 1-
antitrypsin (AAT) and albumin. Results shown in each panel are represen-
tative of three independent experiments. For each experiment shown in 
panels A–C, B cells were pooled from at least two mouse spleens.JEM VOL. 206, October 26, 2009 
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1-antitrypsin and albumin into the media at their usual rates 
and quantities (Fig. 3 E). BiP cleavage by SubAB thus does 
not lead to a general block of the secretory pathway.
a  more  general  consequence  of  SubAB  treatment.  BiP  is 
cleaved in SubAB-treated HepG2 cells to an extent similar to 
that seen in B cells (Fig. 3 D), but these cells still secrete 
Figure 4.  SubAB blocks secretion of IgM, but not intracellular transport of class I MHC molecules. (A) 3-day LPS-stimulated MD4 B cells were labeled 
with [35S]methionine and [35S]cysteine for 10 min in the presence of mutant or native SubAB, chased for the indicated times, and lysed. Total lysates were ana-
lyzed by SDS-PAGE. (B) Lysates (A) were used for immunoprecipitations with antibodies against  or . (C) Band intensities of  (immunoprecipitated with -) 
and  (immunoprecipitated with -) were quantified using a phosphorimager, and the ratio was determined by comparing to the total  or  signal at time 
point zero. (D) 3-day LPS-stimulated B cells were radiolabeled for 10 min in the presence of mutant or native SubAB, and chased for the indicated times. Culture 
media from each chase point were used for immunoprecipitations with antibodies against  or . (E) Band intensities of  (immunoprecipitated with -) and  
(immunoprecipitated with -) were quantified using a phosphorimager, and the obtained raw numbers were plotted. (F) Lysates (A) were also used for immuno-
precipitations of the class I MHC heavy chains. CHO, high-mannose glycans; CHO*, complex-type glycans. Results shown in A, B, D, and F are representative of 
three independent experiments. For each experiment shown in A, B, D, and F, B cells were pooled from at least two mouse spleens.2434 SUBTILASE CYTOTOXIN BLOCKS ANTIBODY SECRETION | Hu et al.
Figure 5.  SubAB blocks the ER-exit of membrane IgM, but not class I MHC molecules. 3-day LPS-stimulated S/ B cells were pretreated with 
mutant or native SubAB for 30 min, labeled with [35S]methionine and [35S]cysteine for 10 min, chased, and lysed. Membrane IgM was immunoprecipitated 
from lysates using anti- and - antibodies (A). Class I MHC molecules were immunoprecipitated using an anti–class I heavy chain antibody (B). Asterisk 
represents molecules bearing complex-type glycans. Longer exposed gels are shown for SubAB-treated samples to emphasize the absence of complex-
type glycan modification on IgM. Results shown in each panel are representative of three independent experiments. For each experiment, B cells were 
pooled from at least two mouse spleens.
To examine in greater detail the kinetics of the blockade 
in IgM secretion, we used a different pulse-chase protocol, 
because  the  30-min  treatment  with  SubAB  already  com-
pletely blocks IgM secretion. We therefore radiolabeled LPS-
stimulated B cells in the presence of SubAB for only 10 min, 
and then chased these cells for 2 h in the continued presence 
of SubAB (Fig. S2 B). In total cell lysates, we identified four 
prominent bands that correspond to  heavy chain, actin, 
Ig, and  light chain (Fig. 4 A). When their intensities were 
compared at the zero time point, none of them were affected 
by SubAB. Both  and  persisted in the lysates from SubAB-
treated B cells at all chase times (Fig. 4 A), consistent with a 
blockade of IgM secretion, as confirmed by immunoprecipi-
tation of  and  from cell lysates and culture supernatants 
(Fig. 4, B–E). Approximately 90% IgM was found to be se-
creted by mutant SubAB-treated B cells after a 2-h chase, but 
only 50% IgM was secreted from SubAB-treated B cells 
(Fig.  4,  B  and  C),  although  exposure  to  SubAB  was  for   
10 min only. Although the anti- antiserum immunoprecipi-
tates only  chains that have been assembled with  chains, 
the anti- antiserum immunoprecipitates the assembled as 
well as the free  chains (Fig. 4, B and D). Secretion of   
 chains as examined by immunoprecipitations using the anti- 
antiserum is blocked even when B cells were exposed to 
SubAB for only 10 min in the course of radiolabeling (Fig. 4, 
B–E). Similar results were obtained for IgM with  light 
chains, obtained from  chain knockout (/) B cells (Fig. 
S3). We then examined whether transport of class I MHC 
molecules  to  the  cell  surface  was  affected  by  exposure  to 
SubAB. Similar amounts of class I MHC molecules in control 
versus SubAB-treated B cells acquire complex-type N-linked 
glycans (Fig. 4 F). SubAB-treated B cells contain higher levels 
of high-mannose-carrying class I MHC (the ER form) when 
compared at the 30- and 60- min chase points, consistent with 
at least some perturbation of ER functions (Lass et al., 2008).
SubAB blocks the ER-exit of membrane IgM, but not  
of class I MHC molecules
We next investigated the trafficking of membrane IgM and 
class I MHC products using S/ B cells. These cells do not 
produce secreted IgM, and therefore allow an easy electro-
phoretic distinction between high-mannose– and complex-
type glycan–carrying membrane IgM (Boes et al., 1998; Hu 
et al., 2009). In cells exposed to SubAB treatment for 30 min, 
class I MHC molecules still acquire complex-type glycans 
(Fig. 5 B), but acquisition of complex-type glycans by mem-
brane IgM is blocked completely (Fig. 5 A), indicating that 
the latter is trapped in the ER.JEM VOL. 206, October 26, 2009 
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We  first  labeled  LPS-activated  B  cells  for  4  h  with 
[35S]methionine and [35S]cysteine to allow robust labeling of 
BiP. We then treated cells with SubAB for 2 h during the 
chase (Fig. S2 C). We used an anti-KDEL antibody to im-
munoprecipitate BiP and observed that the anti-KDEL anti-
body immunoprecipitated both intact BiP and the C-terminal 
BiP fragment (Fig. 6 A). Indeed, when BiP is cleaved, its 
C-terminal fragment is found in a complex with  chains (Fig. 6, 
A and B). Similar association occurs between the C-terminal 
BiP fragment and  chains when / B cells are exposed 
to SubAB (Fig. S4). BiP favors binding to newly synthesized 
 chains (Knittler and Haas, 1992). To investigate how 
SubAB-cleaved C-terminal BiP fragment acts on newly syn-
thesized  chains, we examined  chains synthesized during 
a 10-min pulse. Intact BiP binds only weakly to newly syn-
thesized  chains (Fig. 6 C), consistent with a transient inter-
action between BiP and  chains (Knittler and Haas, 1992; 
SubAB blocks IgM secretion by sequestration of newly 
synthesized light chains in the ER
In mice, 90–95% of B cells synthesize  light chains, and the 
remainder express  light chains. Although free  and  light 
chains can exit the ER and complete the secretory pathway, exit 
of  heavy chains from the ER requires their correct assembly 
with light chains (Vanhove et al., 2001). Because secretion of 
free  chains in MD4 and S/ B cells is blocked by SubAB 
(Figs. 3 A and 3C), the failure of  heavy chains to leave the ER 
might be caused by retention of  chains, and therefore also of 
the  chains bound to them. The behavior of the  chain may 
thus hold the key to understanding how SubAB affects IgM se-
cretion. Because BiP is the only known substrate for SubAB in 
the ER (Paton et al., 2006; Fig. 1), we hypothesized that SubAB-
mediated BiP cleavage products might trap  chains in the ER, 
although a direct effect of BiP cleavage on immunoglobulin 
heavy chains remains a possibility as well.
Figure 6.  The C-terminal BiP cleavage fragment retains  light chains in the ER. (A) 3-day LPS-stimulated S/ B cells were labeled with 
[35S]methionine] and [35S]cysteine for 4 h, washed with PBS, and treated with mutant or native SubAB for the indicated times. Immunoprecipitations were 
performed using an anti-KDEL antibody. In addition to BiP, the anti-KDEL antibody retrieves additional polypeptides, but none of these are affected by 
SubAB. (B) In a similar but independent experiment, proteins immunoprecipitated with the anti-KDEL antibody were eluted and reimmunoprecipitated 
with an anti- antibody. (C) 3-day LPS-stimulated S/ B cells were labeled with [35S]methionine and [35S]cysteine for 10 min and chased in the pres-
ence of mutant or native SubAB for the indicated times. Lysates were immunoprecipitated with the anti-KDEL antibody. Asterisk marks an unidentified 
polypeptide. Results shown in each panel are representative of three independent experiments. For each experiment, B cells were pooled from at least two 
mouse spleens.2436 SUBTILASE CYTOTOXIN BLOCKS ANTIBODY SECRETION | Hu et al.
of high affinity, because the BiP– complex survives immuno-
precipitation in a buffer containing 0.1% SDS and is stable 
in cells for at least 4 h (Fig. 6 B). This result explains why 
no secretion of  chains was observed from SubAB-treated 
Knittler et al., 1995; Skowronek et al., 1998). However, the 
SubAB-cleaved C-terminal BiP fragment binds strongly to 
these newly synthesized  or  chains (Fig. 6 C and Fig. S5). 
Binding of the C-terminal BiP fragment to  chains must be 
Figure 7.  SubAB blocks the secretion of antibodies, but not of IL-6. 3-day LPS-stimulated wild-type and S/ B cells were washed, counted, 
aliquoted into 96-well plates with fresh media containing mutant or native SubAB, and incubated for 4 h (black bars) or 24 h (gray bars). The levels of 
secreted IgM (A), IgG1 (B), IgG2a (C), IgG2b (D), IgA (E), Ig (F), or Ig (G) in culture media at each time point were determined by ELISA. Separate aliquots 
of cells were treated for 24 h with SubAB plus an antibody that blocks IL-6 receptor (IL-6R) to prevent internalization of secreted IL-6 via the IL-6R. The 
levels of IL-6 in culture media were measured by ELISA (H). Results (means ± SD) shown in each panel are representative of two independent experiments. 
For each experiment, B cells were pooled from two spleens of each genotype.JEM VOL. 206, October 26, 2009 
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trol, including dislocation of misfolded proteins from the ER. 
SubAB uses 21 integrin as a receptor to enter cells (Yahiro 
et al., 2006) and is transported to the ER by a clathrin- 
dependent retrograde pathway (Chong et al., 2008). Because 
SubAB reaches the ER by retrograde transport, it might ar-
rive preferentially in those ER subregions dedicated to bio-
synthetic activities and fail to reach all subdivisions of the ER 
equally efficiently, even though BiP might be present at those 
locations at steady-state. This would explain the discrepancy 
between the extent of BiP cleavage and the extent of inhibi-
tion of immunoglobulin secretion and emphasize the utility 
of SubAB to explore the ER physiology.
BiP is one of several chaperones that assist protein folding 
in the ER. SubAB presents a unique tool for functional elimi-
nation of BiP in the absence of a (conditional) knockout allele 
in mice, thus creating an opportunity to investigate BiP func-
tions in different cell types (Paton et al., 2006; Buchkovich   
et al., 2008; Lass et al., 2008; Morinaga et al., 2008; Wolfson 
et al., 2008). BiP binds immunoglobulin heavy chains produced 
by B cells (Haas and Wabl, 1983), and its cleavage by SubAB 
profoundly affects B cell function. Surface display of mem-
brane IgM is blocked by SubAB treatment, and SubAB does 
so by causing retention of IgM in the ER (Fig. 5 A). A differ-
ent type I integral membrane protein, the class I MHC mole-
cule, is displayed at the B cell surface with a slight delay, but no 
signs of complete inhibition of intracellular transport (Fig. 5 B). 
SubAB-treated B cells continue to secrete IL-6 (Fig. 7 H), and 
the assembly of Ig with Ig is not affected (Fig. S7). Folding 
or assembly of IL-6, class I MHC molecules, Ig and Ig 
must therefore be largely BiP-independent. Even though 
secretion of immunoglobulins is blocked, the function of the 
secretory pathway remains largely intact.
How does the C-terminal BiP fragment retain light chains 
in the ER? Substrate binding at the C-terminus of HSP70 
is tightly regulated by its NBD at the N-terminus (Schmid 
et al., 1994; Greene et al., 1995; Zhu et al., 1996; Voisine et al., 
1999). The structure of a functionally intact bovine Hsc70, 
containing both the NBD and the SBD, shows the interac-
tion between the two domains (Jiang et al., 2005). Likewise, 
BiP contains an SBD and a regulatory NBD, and introduc-
tion of the mutation R197E in the NBD of BiP compromises 
NBD–SBD domain interactions and substrate release from 
the SBD (Awad et al., 2008). Intact BiP binds only transiently 
to light chains (Knittler and Haas, 1992; Knittler et al., 1995; 
Skowronek et al., 1998). However, the SubAB-cleaved 
C-terminal BiP fragment, which contains only the SBD, binds 
strongly and stably to newly synthesized light chains (Fig. 6 C 
and Fig. S5). We propose the following model for how se-
questration of light chains by SubAB may occur (Fig. 8). (a) 
BiP binds to nascent light chains through its C-terminal SBD, 
and normal cycles of ATP binding/hydrolysis in the NBD 
mediate conformational changes in the SBD, allowing tran-
sient interaction between BiP and light chains. (b) SubAB 
cleaves BiP. With the loss of its NBD, the C-terminal SBD 
undergoes the usual conformational change, and its associa-
tion with the light chain is now firmly locked in. Because 
B cells (Fig. 3, A and C). None of the available antibodies 
against BiP that are suitable for immunoblotting immunopre-
cipitate the N-terminal BiP fragment, making the character-
ization of its associated molecules impossible at this time. 
However, we could show indirectly that  and  chains bind 
only to the full-length BiP and C-terminal BiP fragment, but 
not to the N-terminal BiP fragment (Fig. S6).
SubAB blocks secretion of antibodies of various isotypes, 
but not IL-6 secretion
We propose that SubAB blocks IgM secretion by sequestering 
 and  chains via the C-terminal BiP fragment. If correct, 
secretion of antibodies of isotypes other than IgM should like-
wise be affected. We examined B cells from wild-type and 
S/ mice for the evidence of altered antibody secretion by 
ELISA after SubAB treatment. Although S/ mice cannot 
secrete IgM, they can still class switch to other isotypes that 
yield secreted immunoglobulins. Consistent with the afore-
mentioned results, secretion of IgM, IgG1, IgG2a, IgG2b, 
IgA, Ig, and Ig were blocked in SubAB-treated B cells 
(Fig. 7, A–G). As a control, we examined the secretion by B 
cells of an immunoglobulin-unrelated protein, IL-6. Given 
that B cells respond to IL-6 in autocrine fashion, we also 
treated B cells with a blocking antibody to the IL-6 receptor 
to more accurately assess the amount of IL-6 secreted without 
the confounding effect of reabsorption. We found that IL-6 
secretion is normal in SubAB-treated B cells (Fig. 7 H).
DISCUSSION
SubAB specifically cleaves BiP and deprives BiP of its func-
tion rapidly (Paton et al., 2006). We assessed the extent of 
cleavage of BiP by exposing LPS-stimulated B cells to SubAB 
for various lengths of time. The extent of BiP cleavage by 
SubAB is never complete in intact cells (Fig. 1, A and B, and 
Fig. 2 A). However, newly synthesized BiP is nearly com-
pletely susceptible to cleavage, whereas the cleaved fraction 
of BiP measured at steady state never exceeded 75% (Fig. 2, 
B–D). This result suggests the existence of distinct pools of 
BiP  as  defined  by  their  susceptibility  to  SubAB  cleavage. 
Newly synthesized BiP that must have remained close to the 
site at which insertion into the ER had occurred is fully sus-
ceptible to cleavage by SubAB, whereas the cleavage-resis-
tant BiP presumably has moved beyond the reach of SubAB. 
This would explain how secretion of newly synthesized 
immunoglobulins can be blocked completely by SubAB with-
out the need for quantitative cleavage of BiP in the ER. If the 
remaining 25% of intact BiP were to remain available for im-
munoglobulin assembly, it is difficult to envision why secre-
tion should not continue, albeit at a reduced rate. The notion 
of functional heterogeneity in the ER is implicit in, for ex-
ample, the existence of smooth and rough versions of the 
ER, but few other aspects of cellular physiology have been 
attributed to distinct subregions of the ER. Biosynthetic as-
pects of ER function, such as membrane insertion, disulfide 
bond formation, and glycosylation might well be relegated to 
areas of the ER distinct from those involved in quality con-2438 SUBTILASE CYTOTOXIN BLOCKS ANTIBODY SECRETION | Hu et al.
SubAB produced by STEC is a versatile tool to study the 
details of how BiP interceded in immunoglobulin folding 
and secretion. A detailed analysis of the biochemical proper-
ties of the BiP cleavage fragments produced by SubAB may 
provide mechanistic insight in how exactly BiP carries out 
its functions.
MATERIALS AND METHODS
Mice. Wild-type C57BL/6, MD4 (Goodnow et al., 1988), and S/ (Boes 
et al., 1998) mice are maintained in our laboratory. All animal protocols 
were approved by the Massachusetts Institute of Technology Committee on 
Animal Care. We thank K. Rajewsky (Harvard Medical School, Boston, 
MA) for providing us with spleens from / mice (Zou et al., 1993).
Antibodies and reagents. Antibodies to N-terminal BiP (Cell Signaling 
Technology), C-terminal BiP (Stressgen), KDEL (Stressgen), p97 (Fitzger-
ald), calreticulin (Stressgen), ERdj3 (Santa Cruz Biotechnology, Inc.), 
human albumin (Sigma-Aldrich), 1-antitrypsin (Novus), actin (Sigma-Aldrich), 
IRE-1 (Cell Signaling Technology), XBP-1 (Santa Cruz Biotechnology, 
Inc.), phospho-eIF2 (Cell Signaling Technology), and e-IF2 (Cell Signal-
ing Technology),  (SouthernBiotech), and  (SouthernBiotech) were ob-
tained commercially. Antibodies against class I MHC heavy chain (p8) and 
PDI were produced in our laboratory. Anti-calnexin antibody was provided 
by D.B. Williams (University of Toronto, Toronto, Canada). The following 
antibodies for ELISA were obtained from BD: IgM, IgG1, IgG2a, IgG2b, 
IgA, Ig, and Ig. The ELISA kit for detection of IL-6 was purchased from 
BD. ELISA plates were read using SpectraMax M2 microplate reader 
(Molecular Devices). LPS and cycloheximide were procured from Sigma-
Aldrich. SubAB and its nontoxic mutant SubAA272B were purified as previ-
ously described (Paton et al., 2004; Talbot et al., 2005).
Cell culture. Naive B lymphocytes were purified from mouse spleen by 
magnetic depletion of CD43-positive cells (Miltenyi Biotec). Naive B cells 
were cultured in RPMI 1640 media containing 10% FBS with or without 
LPS (20 µg/ml).
SDS-PAGE and immunoblot. B cells were treated with SubAB (0.1 
µg/ml) for the indicated times and lysed in conventional RIPA buffer sup-
plemented with protease inhibitors (Calbiochem). Lysates were cleared at 
16,000 g for 10 min at 4°C, resolved by SDS-PAGE (10% acrylamide), and 
electrophoretically transferred onto a nitrocellulose membrane, which was 
then blocked with 5% nonfat milk in PBS-T (PBS containing 0.05% Tween 20, 
pH 7.4) before incubation with a primary antibody. After incubating with 
horseradish peroxidase (HRP)–conjugated secondary antibody (Southern-
Biotech), the PBS-T–washed membrane was developed using the Western 
Lightning Chemiluminescence Reagent PLUS system (PerkinElmer).
Pulse-chase labeling and immunoprecipitation. 3-day LPS-stimulated 
B cells were starved in methionine- and cysteine-free media containing dia-
lyzed serum for 1 h, and then pulse labeled for 10 min with 250 µCi/ml of 
[35S]methionine and [35S]cysteine in the presence of SubAB or its nontoxic 
mutant counterpart. In some experiments, cells were radiolabeled for 4 h or 
treated with SubAB before pulse labeling or only during the chase period, as 
indicated in the figure legends. At the end of each chase point, cells were 
rinsed twice with PBS and lysed in conventional RIPA buffer containing 
protease inhibitors. Precleared lysates were incubated with a primary anti-
body and protein G-agarose beads, washed, eluted from the beads using re-
ducing Laemmli SDS-PAGE sample buffer, and analyzed by SDS-PAGE 
and fluorography. Quantitation was performed by phosphorimaging.
Online supplemental material. Fig. S1 shows that prolonged exposure to 
SubAB inhibits protein synthesis in B cells. Fig. S2 summarizes the radiola-
beling strategies. Fig. S3 shows that SubAB blocks secretion of IgM contain-
ing  light chains. Fig. S4 shows that the SubAB-cleaved C-terminal BiP 
substrate release from the SBD requires ATP binding to the 
NBD, which is absent from the cleaved form of BiP, the 
SubAB-cleaved C-terminal SBD remains tightly associated 
with light chains as well as heavy chains. (c) Immunoglobulin 
heavy and light chains are thus sequestered by the C-terminal 
BiP fragment. The C-terminal BiP-bound  and  light chains 
likely recycle between the ER and the Golgi apparatus via 
the KDEL receptor.
STEC cause human gastrointestinal diseases, which in se-
rious cases can lead to systemic complications such as HUS 
(Nataro and Kaper, 1998; Paton and Paton, 1998) and splenic 
atrophy (Paton et al., 2004; Wang et al., 2007). SubAB pro-
duced by STEC is sufficient to cause such a syndrome (Paton 
et al., 2004; Wang et al., 2007). Here, we show that STEC 
use SubAB to cause retention of  and  light chains and their 
associated heavy chains in the ER (Figs. 6; 7, F and G; S4; and 
S5). By sequestering both  and  light chains, SubAB inhib-
its secretion of antibodies of all isotypes, including IgA (Fig. 7 E). 
The protective function of IgA-producing B cells, primarily 
found in gut-associated lymphoid tissues, will thus be com-
promised. Inactivation of IgA-producing B cells in the gut 
may be beneficial to STEC to allow colonization. HUS usu-
ally develops in the late stages of STEC-caused gastrointesti-
nal diseases; nevertheless, once SubAB enters the blood and 
makes its way to the spleen or bone marrow, all B cells will 
cease secreting antibodies. This specific block in antibody se-
cretion is an obvious means of immune evasion for STEC. 
Our finding provides a rational explanation for the observa-
tion that calves infected by STEC quickly lose their Shiga 
toxin–specific antibodies in the sera (Fröhlich et al., 2009).
Figure 8.  A model for the mode of action of SubAB. SubAB cleaves 
BiP into two segments, one containing the NBD, and the other containing 
the SBD. The SBD consists of short stretches of hydrophobic amino acids 
that allow its binding to unfolded/misfolded proteins. SubAB cleaves BiP, 
resulting in sequestration of immunoglobulin light chains through inter-
actions with its cleaved product, the SBD of BiP.JEM VOL. 206, October 26, 2009 
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